Oncology

Immunotherapy showed promise in first- and second-line therapy for patients with metastatic bladder cancer.

Survey findings show a high level of integration of palliative care in advanced cancer patients.

Top news of the day from across the health care landscape.

Xtandi’s revised label will include results a study showing improve progression-free survival in prostate cancer.

Experimental treatment uses mRNA expression from tumors to identify responders.

No change in prostate-specific antigen tests for cancer was found before and after new screening guidelines.

Top news of the day from across the health care landscape.

Researchers examine interventions that may improve adherence in chronic viral hepatitis care.

Hookah bars are on the rise around the world despite their being associated with many health risks.

Top news of the week in oncology and cancer drug development.

New data indicates men of African American and Hispanic descent are less likely to undergo therapy for prostate cancer compared with Caucasian men.

Targeting the uracil-DNA glycosylase enzyme may help treat certain types of non-Hodgkin’s lymphoma.

Top news of the day from across the health care landscape.

Efficacy and safety data shows encouraging results for rucaparib in BRCA-mutation ovarian cancer.

Obstacles exist in making testing and treatment for hepatitis C routine practice in prison.

In case you missed it, here's the hottest news in pharmacy this week:

Treating financial toxicity in cancer patients similarly to other side effects could improve outcomes.

Lartruvo with doxorubicin significantly improves overall survival in patients with soft tissue sarcoma.

Relapsed metastatic head-and-neck cancer patients who received nivolumab experienced a reduction in symptoms.

Inhibiting Ran-GTP was associated with reversing and preventing treatment-resistant cancers.

Tecentriq is the first anti-PDL1 cancer immunotherapy approved for metastatic non-small cell lung cancer.

Major pathological tumor regression was experienced by 40% of patients receiving neoadjuvant immunotherapy before resection.

Tecentriq provides new option for patients with previously treated metastatic lung cancer.

Nivolumab prior to tumor resection found safe in patients with early non-small cell lung cancer.

Tecentriq is the first anti-PDL1 cancer immunotherapy approved for metastatic non-small cell lung cancer.

Niraparib significantly improved outcomes of platinum-sensitive recurrent ovarian cancer in landmark trial.

Atezolizumab is a PD-L1 inhibitor that uses the immune system to fight cancer.

A unique pattern of motion by repair proteins allows them to rapidly scan long DNA and flag repair machinery in condition that can lead to skin cancer.